Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70779 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2026. Written by Mohamed H Eldesouki and 8 co-authors. Institution: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Major MEDLINE topics: Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, Myeloproliferative Disorders. Cited 2 times so far (Crossref); 59 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Inflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation.
Aim
We evaluated the incidence of MPNs among patients with IBD and clinical outcomes of IBD–MPN coexistence.
Methods
Two retrospective cohort analyses were conducted using the TriNetX database. First, adults with ulcerative colitis (UC) or Crohn's disease (CD) were compared with matched non‐IBD controls to estimate incident MPN risk. A coexistence second analysis included patients with UC or CD who developed MPNs and then were matched to IBD without MPN controls to assess 5‐year outcomes, including IBD‐related complications, surgical interventions, colorectal cancer (CRC) and primary sclerosing cholangitis (PSC). Medication subgroup analyses were performed to evaluate associations with MPN risk.
Results
After matching, 3873 patients with UC–MPN and 3474 patients with CD–MPN were included. Compared with matched non‐IBD controls, incident MPN risk was higher in UC (HR 1.60, p = 0.01) and CD (HR 1.56, p < 0.001). In CD, MPN coexistence was associated with higher risks of CRC (HR 1.52, p = 0.012), intestinal fistula (HR 2.84, p < 0.001), obstruction (HR 2.05, p < 0.001), perforation (HR 2.37, p < 0.001), small bowel resection (HR 3.69, p < 0.001) and colectomy (HR 2.10, p < 0.001). In UC, MPN coexistence was associated with higher risks of CRC (HR 1.50, p = 0.001), PSC (HR 1.75, p = 0.03) and pouchitis (HR 1.68, p = 0.003). Exposure to thiopurines (HR 1.28, p < 0.001) was associated with increased MPN risk, whereas TNF, IL‐23 and JAK inhibitors were not.
Conclusions
IBD is associated with increased MPN risk, and IBD–MPNs coexistence is associated with worse IBD‐related complications and malignancy risk.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
- Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.
- Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Haematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID profiles: Mohamed H Eldesouki, Ahmed Ibrahim
Cite
APA
Eldesouki, M. H., Ibrahim, A., Marey, M. M., Francis, F. F., Alsakarneh, S., Ayala, E., Shaukat, A., Farraye, F. A., & Hashash, J. G. (2026). Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70779
Vancouver
Eldesouki MH, Ibrahim A, Marey MM, Francis FF, Alsakarneh S, Ayala E, et al. Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70779
BibTeX
@article{Eldesouki2026,
author = {Eldesouki, Mohamed H and Ibrahim, Ahmed and Marey, Muhammed M and Francis, Fadi F and Alsakarneh, Saqr and Ayala, Ernesto and Shaukat, Aasma and Farraye, Francis A and Hashash, Jana G},
title = {Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi‐Centre Matched Analysis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70779}
}
EUVIMED